NO signaling in the CNS: from the physiological to the pathological
76 SmithE
Here is a summary of the data for Alabama: Medicaid spending on GLP-1s (past 12 months): $43,100,970 Medicaid spending on GLP-1s (YoY change): +107% Medicaid spending on GLP-1s per enrollee (past 12 months): $55 Total Medicaid enrollment: 787,325 Wegovy coverage (obesity-indicated): Yes Zepbound coverage (obesity-indicated): No Saxenda coverage (obesity-indicated): No Ozempic coverage (Type 2 diabetes-indicated): Yes Mounjaro coverage (Type 2 diabetes-indicated): Yes Rybelsus coverage (Type 2 diabetes-indicated): Yes For reference, here are the statistics for the entire United States: Medicaid spending on GLP-1s (past 12 months): $3,452,602,033 Medicaid spending on GLP-1s (YoY change): +142% Medicaid spending on GLP-1s per enrollee (past 12 months): $48 Total Medicaid enrollment: 72,429,055 Wegovy coverage (obesity-indicated): 34 states Zepbound coverage (obesity-indicated): 16 states Saxenda coverage (obesity-indicated): 19 states Ozempic coverage (Type 2 diabetes-indicated): 51 states* Mounjaro coverage (Type 2 diabetes-indicated): 46 states* Rybelsus coverage (Type 2 diabetes-indicated): 46 states *Including District of Columbia Methodology The data used in this study comes from IRIS by Real Chemistrya proprietary market intelligence platform fueled by billions of data points, including medical, hospital, and pharmacy claims covering more than 300 million U.S
Sinh kh dng l t l hot cht c hp thu vo mu
& Cerutti, J
Links mentioned in this episode Perimenopause weight loss plan Insulin resistance episode: what labs to check Perimenopause weight loss episode Two-part sleep series (why sleep shifts appetite, cortisol, and metabolic health): Part 1, Part 2 Thyroid deep dives with McCall McPherson (thyroid panels and GLP-1 considerations)
